Andrea Sloan, Prominent Ovarian Cancer Patient Dies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ANDREA SLOAN, an ovarian cancer patient whose efforts to get access to a BioMarin drug attracted national media attention, died from complications of pneumonia Jan. 1 (The Cancer Letter, Nov. 8, 2013). Sloan, an Austin attorney, was 45.

YOU MAY BE INTERESTED IN

FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login